H. Lundbeck A/S (commonly known simply as Lundbeck) is a Danish international pharmaceutical company engaged in the research and development, production, marketing, and sale of drugs for the treatment of disorders in the central nervous system (CNS), including depression, schizophrenia, Alzheimer's disease and Parkinson's disease.Headquartered in Copenhagen, Denmark, Lundbeck has international production facilities in Denmark, Italy and France and affiliates or sales offices in more than 50 countries. Lundbeck employs around 5,000 people globally (as of 2017), and the company’s products are registered in more than 100 countries worldwide.In 2017, the company's revenue was DKK 17.2 billion (€2.3 billion). Lundbeck is listed on the Copenhagen Stock Exchange (CSE). Lundbeck is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
The efficacy and tolerability of vortioxetine tablets for depression is established, but prospective data for the oral drop formulation were unavailable. This analysis compared the effectiveness, tolerability and dosing patterns of vortioxetine tablet and drop formulations for the treatment of major depressive episodes in Swiss real-world practice. A post hoc analysis of a prospective, non-interventional study in adults experiencing a major depressive episode (MDE) was conducted. Depression symptoms, functioning, dosing patterns and tolerability were assessed using unanchored Montgomery–Åsberg Depression Rating Scale items, the Clinical Global Impression-Severity (CGI-S) scale, a four-point functioning scale, and incidence of adverse drug reactions (ADRs). Statistical tests included two-sample t-tests, Fisher’s exact test, Chi-square test and general linear modelling. Of 225 patients, 60 (26.7
This analysis aimed to evaluate the efficacy of brexpiprazole 2 or 3 mg/day for the treatment of agitation associated with dementia due to Alzheimer’s disease, on the basis of pooled clinical trial data. Data were pooled from two similarly designed, phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled trials of fixed-dose brexpiprazole in participants in care facilities or community-based settings who had agitation associated with dementia due to Alzheimer’s disease. Efficacy outcomes included Cohen-Mansfield Agitation Inventory (CMAI) total score (which measures the frequency of 29 different agitation symptoms), Clinical Global Impression-Severity of illness (CGI-S) score, CMAI factor scores (aggressive behaviors, physically nonaggressive behaviors, and verbally agitated behaviors), and response rates. A sensitivity analysis included a third trial with flexible dosing. In total, 621 participants were randomized (brexpiprazole, 368; placebo, 253), and completion rates were 320/368 (87.0
The Unified Multiple System Atrophy Rating Scale (UMSARS) is widely used as an outcome measure in MSA trials, but it has limitations for clinical trial use. To address these, we developed the Multiple System Atrophy Combined Outcome Assessment (MuSyCA), a comprehensive multimodal tool for disease-modifying MSA trials. The purpose of this manuscript is to describe the development and validation plan for MuSyCA, with emphasis on its structure, intended use, and assessment of reliability, validity, and sensitivity in tracking disease progression. The development of MuSyCA followed a multistep process. Candidate outcome assessments were identified through systematic literature review and analysis of longitudinal data from large MSA cohorts. Content was refined through multiple Delphi-like consensus rounds involving MSA experts, patient advocacy groups representatives, and industry stakeholders. Cognitive interviews conducted in 20 patients with MSA evaluated the clarity and clinical relevance of patient- and clinician-reported outcomes; feedback was incorporated into a subsequent version of the MuSyCA. Validation is ongoing and includes assessment of construct validity, internal consistency, test–retest reliability, and responsiveness. Longitudinal analyses to determine sensitivity to change over time are ongoing. MuSyCA combines patient- and clinician-reported outcomes, biomarkers (neurofilament light chain, neuroimaging), and performance-based measures to capture subjective and objective aspects of MSA progression, enhancing its utility to detect treatment effects in clinical trials. MuSyCa is not intended to be used in clinical practice. MuSyCA offers a multidimensional approach to MSA assessment, supporting precise, disease-relevant evaluations in trials of putative disease-modifying therapies. Its validation will provide a standardized multimodal outcome measure, advancing MSA therapeutic development.
In biomedical time-series classification, machine learning models often suffer from deteriorating accuracy and calibration due to distribution shift. We investigate to what degree Bayesian-inspired deep learning improves robustness through Bayesian model averaging (BMA). Using rodent sleep scoring as a case study, we evaluate BMA under distribution shifts in genotype, laboratory, and species. We systematically compare nine approximate inference methods spanning single- and multi-basin approaches across two neural network backbones on in-distribution (ID) data and five out-of-distribution (OOD) datasets. In our results, multi-basin methods perform best, outperforming baselines and single-basin methods. Compared with point estimates, BMA generally improves OOD accuracy and calibration across both architectures, while yielding only modest ID gains. It also often improves selective prediction and OOD and artifact detection, but, interestingly, not inter-rater disagreement detection.